Abstract:Objective: The aim of this study is to assess the postoperative efficacy of the combined administration of dienogest (DNG) and gonadotropin-releasing hormone agonists (GnRH-a) in patients diagnosed with endometriosis (EMS), while acknowledging the extensive use of DNG in the extended therapeutic management of EMS. Methods: In this retrospective study, a cohort of 154 patients who underwent conservative surgical intervention for EMS were scrutinized. The cohort was stratified into two distinct groups based on their prescribed pharmacological regimens. Group A, 70 patients received postoperative oral administration of DNG at a dosage of 2 mg/day, whereas Group B, 84 patients underwent treatment involving 3 to 4 injections of GnRH-a post-surgery, followed by DNG therapy. Parameters assessed included pelvic pain visual analog scale (VAS) scores, quality of life metrics (EHP-5), and the incidence of adverse reactions within both groups. Results: Both groups exhibited sustained low VAS scores following the prescribed treatments. The predominant occurrence of adverse bleeding patterns manifested predominantly within the initial 6 months of the treatment. Notably, Group B demonstrated a significantly diminished of experiencing frequent and irregular bleeding in comparison to the DNG group (20.0% vs. 8.3%, 12.9% vs. 3.6%, p < 0.05). The administration of GnRH-a did not exacerbate the impact on bone health. Subsequent to health promotion interventions, the incidence of weight gain in both groups declined to 7.1% during the 6-month follow-up ( p < 0.05). Group B exhibited a 100% satisfaction rate with the treatment, concomitant with a noteworthy reduction in EHP-5 scores ( p < 0.05). Patients with deep infiltrating endometriosis (DIE) nodules displayed marginally higher postoperative VAS scores than their non-DIE counterparts (0.89 ± 0.96 vs. 0.49 ± 0.78). However, with sustained medication use, pain scores within the DIE group exhibited a continual decrease, maintaining a low level of 0.29 ± 0.67 at 12 months and beyond. Conclusion: The short-term adjunctive use of GnRH-a prior to DNG treatment postoperatively in patients with EMS proves efficacious in mitigating early adverse bleeding, enhancing patient adherence, and improving overall quality of life. Notably, this therapeutic approach demonstrates favorable safety profiles and is equally effective in patients with DIE.

NLRP3 concentration, oxidants, and antioxidants in plasma of endometriosis patients undergoing treatment with dienogest

Nlrp3 Inflammasome Activation Of Mast Cells By Estrogen Via The Nuclear-Initiated Signaling Pathway Contributes To The Development Of Endometriosis

Decreased Levels of Peritoneal Interleukin-1 Receptor Antagonist in Patients with Endometriosis and Disease-Related Dysmenorrhea.

Prolonged Gonadotropin-Releasing Hormone Agonist Therapy Reduced Expression of Nitric Oxide Synthase in the Endometrium of Women with Endometriosis and Infertility

Role of Brain-Derived Neurotrophic Factor in Endometriosis Pain

Elevated Immunoreactivity of RANTES and CCR1 Correlate with the Severity of Stages and Dysmenorrhea in Women with Deep Infiltrating Endometriosis.

CGRP neuropeptide levels in patients with endometriosis-related pain treated with dienogest: a comparative study

Atherosclerosis-related biomarkers in women with endometriosis: The effects of dienogest and oral contraceptive therapy

[Clinical Study of Dienogest in the Treatment of Refractory Endometriosis-Associated Pain].

Risk factors for non-response and discontinuation of Dienogest in endometriosis patients: A cohort study

Oxidative stress and antioxidant capacity in patients with endometrioma

Follicular Fluid Progesterone Downregulated HPGD and COX2 in Granulosa Cells Via Suppressing NF-ĸB in Endometriosis

Gut microbiota imbalance and its correlations with hormone and inflammatory factors in patients with stage 3/4 endometriosis

Efficacy and safety of dienogest in the treatment of deep infiltrating endometriosis: A meta-analysis

A higher number of exhausted local PD1+, but not TIM3+, NK cells in advanced endometriosis

Dienogest in conjunction with GnRH-a for postoperative management of endometriosis

Genome-Wide Gene Expression Profiling Reveals the Direct Effect of Dienogest on Ovarian Endometriotic Stromal Cells

Positive correlation between NLR and PLR in 10,458 patients with endometriosis in reproductive age in China

Dienogest: a new therapeutic agent for the treatment of endometriosis

Long-Term Administration of Dienogest for the Treatment of Pain and Intestinal Symptoms in Patients with Rectosigmoid Endometriosis

Anti-inflammatory, antioxidant, antiangiogenic, and therapeutic efficacy of neroli oil in rats with endometriotic lesions